

Addendum

Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2024

In addition to the recommendations presented in the previous sections of this immunization schedule, ACIP has approved the following recommendations by majority vote since October 26, 2023. The following recommendations have been adopted by the CDC Director and are now official. Links are provided if these recommendations have been published in *Morbidity and Mortality Weekly Report (MMWR)*.

Vaccines	Recommendations	Effective Date of Recommendation*
COVID-19 (Moderna, Pfizer-BioNTech, Novavax)	<ul style="list-style-type: none">ACIP recommends 2024–2025 COVID-19 vaccines as authorized or approved by FDA in persons ≥ 6 months of age.	June 27, 2024
Influenza	<ul style="list-style-type: none">ACIP reaffirms the recommendation for routine annual influenza vaccination of all persons aged ≥ 6 months who do not have contraindications.ACIP recommends high-dose inactivated (HD-IV3) and adjuvanted inactivated (aIV3) influenza vaccines as acceptable options for influenza vaccination of solid organ transplant recipients aged 18 through 64 years who are on immunosuppressive medication regimens, without a preference over other age-appropriate IV3s or RIV3.	June 27, 2024
Vaxelis (DTaP-IPV-Hib-HepB)	<ul style="list-style-type: none">ACIP recommends DTaP-IPV-Hib-HepB (Vaxelis[®]) should be included with PRP-OMP (PedvaxHIB[®]) in the preferential recommendation for American Indian and Alaska Native infants based on the <i>Haemophilus influenzae</i> type b (Hib) component.	June 26, 2024

*The effective date is the date when the CDC director adopted the recommendation and when the ACIP recommendation became official.